Kyriacos Athanasiou Named to Histogenics Scientific Advisory Board

Distinguished Professor and Chair Kyriacos Athanasiou

Kyriacos Athanasiou has been named to the Scientific Advisory Board of Histogenics Corporation. Histogenics Corporation, a privately held regenerative medicine company, is advancing NeoCart®, an autologous bioengineered neocartilage grown outside the body using the patient’s own cells for the regeneration of cartilage lesions, and VeriCart™, a three-dimensional cartilage matrix to stimulate cartilage repair in a simple, one-step procedure.

“This advisory board represents some of the most prolific researchers,publishers and innovators in regenerative medicine with an extensive range of expertise in cartilage and soft-tissue repair, biomaterial scaffolds, fibroblast growth factor variants and stem cell research,” said Patrick O’Donnell, President and Chief Executive Officer of Histogenics. “Each member will play a critical role in guiding our research and product development pipeline initiatives, including our next generation NeoCart On-Demand™ single step cartilage tissue implant, as we continue to build Histogenics’ leadership position in articular cartilage and soft tissue regeneration.”

border